High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 3163-3164

  de Velde, Femke ^a   Emonts, Marieke ^b,c,d   Verbruggen, Sascha ^b   van der Sijs, Heleen ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bioavailability; Drug adverse events; Drug monitoring; Drug toxicity; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CIPROFLOXACIN; CREATININE; MEROPENEM; TOBRAMYCIN;

ATELECTASIS; CANDIDIASIS; CASE REPORT; CHILD; CONTINUOUS HEMOFILTRATION; DIURESIS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPYEMA; EXTRACORPOREAL OXYGENATION; FEVER; HUMAN; KIDNEY FAILURE; LETTER; MEDICAL NEBULIZER; OLIGURIA; OUT OF HOSPITAL CARDIAC ARREST; OXYGEN CONSUMPTION; PNEUMOTHORAX; PSEUDOMONAS PNEUMONIA; RESPIRATORY DISTRESS; RESUSCITATION; RHABDOMYOLYSIS; SAMPLING ERROR; SCHOOL CHILD; VENTILATOR ASSOCIATED PNEUMONIA; BLOOD; INHALATIONAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CHILD; HUMANS; RENAL INSUFFICIENCY; TOBRAMYCIN;

EID: 84931315614     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku260     Document Type: Letter

References (10)

1. Pai VB, Nahata MC. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol 2001; 32: 314-27.
2. Geller DE, Pitlick WH, Nardella PA et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-26.
3. Barker AF, Couch L, Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-5.
4. Redman S, Wainwright C, Stacey S et al. Misleading high tobramycin plasma concentrations can be caused by skin contamination of fingerprick blood following inhalation of nebulized tobramycin (TOBIw). Ther Drug Monit 2005; 27: 205-7.
5. Abdulhamid I, Wise TL, Andrews S et al. Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant. Pharmacotherapy 2008; 28: 939-44.
6. Ahya VN, Doyle AM, Mendez JD et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005; 24: 932-5.
7. Edson RS, Brey RH, McDonald TJ et al. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004; 79: 1185-91.
8. Kahler DA, Schowengerdt KO, Fricker FJ et al. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003; 23: 543-5.
9. Patatanian L. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr Infect Dis J 2006; 25: 276-8.
10. Langley A, Cottingham L. Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation. Am J Health Syst Pharm 2011; 68: 1385-6.